Director/PDMR Shareholding
11 February 2022 15:30 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 10 February 2022, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot, Chief Executive Officer. The AZIP award was granted on 28 March 2014 and was subject to a four-year performance period followed by a four-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 100% of the AZIP award entering